Radiation therapy with once-weekly gemcitabine in pancreatic cancer: current status of clinical trials (Q35162487)

6 August 2017

1 reference

title

Radiation therapy with once-weekly gemcitabine in pancreatic cancer: current status of clinical trials (English)

1 reference

Adaptive radiation therapy

6 August 2017

main subject

0 references

1 reference

Cornelius J McGinn

1

1 reference

6 August 2017

Mark M Zalupski

series ordinal

2

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

International Journal of Radiation Oncology Biology Physics

6 August 2017

published in

1 reference

6 August 2017

volume

56

1 reference

6 August 2017

issue

4 Suppl

1 reference

6 August 2017

page(s)

10-15

1 reference

Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900449-8

7 January 2021

The effect of 2'-2' difluorodeoxycytidine (dFdC, gemcitabine) on radiation-induced cell lethality in two human head and neck squamous carcinoma cell lines differing in intrinsic radiosensitivity.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900449-8

7 January 2021

Radiosensitizing nucleosides

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900449-8

7 January 2021

Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900449-8

7 January 2021

Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900449-8

7 January 2021

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900449-8

7 January 2021

Maximizing therapeutic gain with gemcitabine and fractionated radiation

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900449-8

7 January 2021

Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900449-8

7 January 2021

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900449-8

7 January 2021

Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900449-8

7 January 2021

Intraoperative and external beam irradiation +/- 5-FU for locally advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900449-8

7 January 2021

The clinical application of a non-axial treatment plan for pancreatic and biliary malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900449-8

7 January 2021

Three-dimensional conformal pancreas treatment: comparison of four- to six-field techniques

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900449-8

7 January 2021

Recent advances in radiation oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900449-8

7 January 2021

10.1016/S0360-3016(03)00449-8

Identifiers

DOI

1 reference

6 August 2017

1 reference